Heparin Panpharma (Heparin Sodium)

Heparin Panpharma is employed in several clinical scenarios where rapid anticoagulation is required.

• Prevention and treatment of venous thromboembolism, including deep‑vein thrombosis and pulmonary embolism.
• Anticoagulation during cardiac surgery, such as cardiopulmonary bypass procedures.
• Anticoagulation for patients undergoing hemodialysis or other extracorporeal circuits.
• Management of acute coronary syndromes when immediate anticoagulation is indicated.
• Prophylaxis of clot formation in patients with atrial fibrillation undergoing invasive procedures.

Adverse reactions to Heparin Panpharma vary in frequency and severity; they are categorized as common or serious based on clinical observations.

Common

• Minor bleeding at the injection site.
• Small decreases in platelet count (thrombocytopenia) without clinical consequences.
• Transient elevation of liver enzymes.
• Nausea or mild headache.

Serious

• Major hemorrhage requiring medical intervention.
• Heparin‑induced thrombocytopenia (HIT) with risk of thrombosis.
• Spontaneous spinal or epidural hematoma.
• Allergic reactions such as urticaria or anaphylaxis.

Before initiating Heparin Panpharma, clinicians should evaluate several precautionary factors to minimize risk.

• Assess baseline coagulation parameters (aPTT, PT/INR) and adjust dosing accordingly.
• Review patient history for prior heparin exposure or known HIT.
• Use caution in patients with active bleeding, recent surgery, or traumatic injuries.
• Monitor renal and hepatic function, as impairment may affect drug clearance.
• Avoid use in pregnancy unless benefits outweigh potential risks, due to limited safety data.
• Consider age‑related dosing adjustments for elderly patients.

Heparin Panpharma may interact with other agents that affect hemostasis or drug metabolism; awareness of these interactions helps guide safe therapy.

Avoid

• Concurrent use of other anticoagulants (e.g., warfarin, direct oral anticoagulants) without careful monitoring.
• Administration with thrombolytic agents such as alteplase or streptokinase.
• High‑dose aspirin or non‑steroidal anti‑inflammatory drugs (NSAIDs) that increase bleeding risk.

Use with caution

• Antiplatelet drugs (clopidogrel, ticagrelor) may potentiate bleeding.
• Glycoprotein IIb/IIIa inhibitors require close observation of platelet counts.
• Certain antibiotics (e.g., vancomycin) have been associated with enhanced anticoagulant effect.